Drug
Inupadenant
Inupadenant: highest development phase Phase 2, developed by iTeos Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- iTeos Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| inupadenant NCT05403385 | Phase 2 | Metastatic NSCLC - Non-Small Cell Lung Cancer |
| Inupadenant NCT05117177 | Phase 1 | Solid Tumor, Adult |
Latest
No recent events.
Follow Inupadenant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.